Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Statement re Offer for Subscription

10 Jan 2022 12:43

RNS Number : 9606X
Maven Income and Growth VCT 3 PLC
10 January 2022
 

Maven Income and Growth VCT 3 PLC and Maven Income and Growth VCT 4 PLC (the Companies)

 

Offers for Subscription - Early Investment Incentive

 

10 January 2022

 

On 20 September 2021, the Companies published a joint Prospectus (comprising a Securities Note, Registration Document and Summary) in relation to offers for subscription of new Ordinary Shares of 10p each (together the "Offers" and each an "Offer").

 

In the Prospectus, it was stated that all valid applications that were received (together with their relevant application monies) by the deadline of 12.00 noon on 28 January 2022 would be eligible to receive an Early Investment Incentive discount under the Offers. Existing Shareholders (and their spouses or partners) in any of the Maven VCTs, including the Companies, at the time the application was received would benefit from an enhanced rate of discount in recognition of their continued support for the Maven VCTs. The levels of discount to be applied would be:

 

· 1.5% of the application amount for Existing Shareholders; and

· 1.25% of the application amount for New Investors.

 

It was also stated that each Company could, in consultation with Maven Capital Partners UK LLP (Maven) and in their absolute discretion, extend the deadline by which applications must be received to be eligible for the Early Investment Incentive under its Offer.

 

The Board of each Company confirms that the deadline by which applications must be received to be eligible for the Early Investment Incentive under their Company's respective Offer has been extended until close of business on Wednesday 2 February 2022. Furthermore, it is anticipated that both Companies will make initial allotments of new Ordinary Shares under their respective Offers as soon as practicable after that date.

 

Further information

 

Any enquiries in respect of the Offers, or requests for copies of the Prospectus documents (available free of charge), should be directed to:

 

Maven Capital Partners UK LLP

Kintyre House

205 West George Street

Glasgow

G2 2LW

 

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Downloadable versions of the Prospectus documents are available from the Maven website at: www.mavencp.com/vctoffer.

Maven Capital Partners UK LLPSecretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRFLFSFLIIILIF
Date   Source Headline
19th Jul 201712:20 pmRNSStatement re Intended Offers for Subscription
19th Jul 201712:20 pmRNSStatement re Intended Offers for Subscription
15th Jun 20174:00 pmRNSDividend Declaration
12th Jun 20174:24 pmRNSTransaction in Own Shares
17th May 20172:33 pmRNSNet Asset Value and Final Dividend
17th May 20172:25 pmRNSResult of AGM
7th Apr 20173:45 pmRNSAnnual Financial Report
2nd Mar 20173:11 pmRNSTransaction in Own Shares
28th Feb 20172:40 pmRNSNet Asset Value and Final Dividend
20th Dec 20164:51 pmRNSTransaction in Own Shares
10th Nov 201611:05 amRNSNet Asset Value(s)
23rd Sep 20165:10 pmRNSTransaction in Own Shares
20th Sep 20164:56 pmRNSTransaction in Own Shares
26th Aug 20164:07 pmRNSHalf-year Report
17th Aug 20162:12 pmRNSNet Asset Value(s)
24th May 20163:06 pmRNSTransaction in Own Shares
27th Apr 20161:50 pmRNSNet Asset Value(s) - Replacement
27th Apr 201612:58 pmRNSResult of AGM
27th Apr 201612:55 pmRNSNet Asset Value(s)
30th Mar 20165:29 pmRNSAnnual Financial Report
22nd Mar 20162:44 pmRNSTransaction in Own Shares
10th Mar 20164:55 pmRNSTransaction in Own Shares
8th Mar 20164:37 pmRNSTransaction in Own Shares
7th Mar 20164:33 pmRNSTransaction in Own Shares
2nd Mar 20164:09 pmRNSNet Asset Value and Proposed Final Dividend
9th Dec 20154:15 pmRNSPortfolio Update and Unaudited Net Asset Value
27th Nov 20154:36 pmRNSTransaction in Own Shares
17th Nov 201512:59 pmRNSTransaction in Own Shares
16th Nov 20152:17 pmRNSTransaction in Own Shares
12th Nov 201510:34 amRNSNet Asset Value(s)
4th Sep 20153:20 pmRNSTransaction in Own Shares
28th Aug 201512:20 pmRNSHalf Yearly Report
24th Aug 20153:39 pmRNSStatement re Dividend Investment Scheme
20th Aug 20154:50 pmRNSTransaction in Own Shares
20th Aug 201511:47 amRNSStatement re Net Asset Value and Dividend
23rd Jun 20154:51 pmRNSTransaction in Own Shares
12th Jun 201510:02 amRNSIssue of Equity
5th Jun 20153:18 pmRNSNet Asset Value(s)
27th May 20159:34 amRNSTransaction in Own Shares
15th May 20152:17 pmRNSTransaction in Own Shares
14th May 201512:38 pmRNSTransaction in Own Shares
13th May 20153:21 pmRNSTransaction in Own Shares
12th May 20154:39 pmRNSNet Asset Value(s)
29th Apr 20152:13 pmRNSDirectorate Change
29th Apr 20152:13 pmRNSResult of AGM
13th Apr 20153:12 pmRNSIssue of Equity
30th Mar 20152:26 pmRNSTransaction in Own Shares
26th Mar 201512:52 pmRNSTransaction in Own Shares
25th Mar 20152:38 pmRNSTransaction in Own Shares
24th Mar 20154:37 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.